Indoleamine 2,3-dioxygenase vaccination

Mads Hald Andersen; Inge Marie Svane

doi:10.4161/2162402X.2014.983770

Indoleamine 2,3-dioxygenase vaccination

21 Citations (Scopus)

Abstract

Indoleamine 2,3-dioxygenase (IDO) is an immunoregulatory enzyme. Remarkably, we discovered IDO-specific T cells that can influence adaptive immune reactions in patients with cancer. Further, a recent phase I clinical trial demonstrated long-lasting disease stabilization without toxicity in patients with non-small-cell lung cancer (NSCLC) who were vaccinated with an IDO-derived HLA-A2-restricted epitope.

Original language	English
Journal	OncoImmunology
Volume	4
Issue number	1
Pages (from-to)	e983770
ISSN	2162-4011
DOIs	https://doi.org/10.4161/2162402X.2014.983770
Publication status	Published - Jan 2015

Access to Document

10.4161/2162402X.2014.983770

Cite this

@article{5a5b3aab680e44249d62f2563f8f30df,

title = "Indoleamine 2,3-dioxygenase vaccination",

abstract = "Indoleamine 2,3-dioxygenase (IDO) is an immunoregulatory enzyme. Remarkably, we discovered IDO-specific T cells that can influence adaptive immune reactions in patients with cancer. Further, a recent phase I clinical trial demonstrated long-lasting disease stabilization without toxicity in patients with non-small-cell lung cancer (NSCLC) who were vaccinated with an IDO-derived HLA-A2-restricted epitope.",

author = "Andersen, \{Mads Hald\} and Svane, \{Inge Marie\}",

year = "2015",

month = jan,

doi = "10.4161/2162402X.2014.983770",

language = "English",

volume = "4",

pages = "e983770",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Taylor and Francis Ltd.",

number = "1",

}

TY - JOUR

T1 - Indoleamine 2,3-dioxygenase vaccination

AU - Andersen, Mads Hald

AU - Svane, Inge Marie

PY - 2015/1

Y1 - 2015/1

N2 - Indoleamine 2,3-dioxygenase (IDO) is an immunoregulatory enzyme. Remarkably, we discovered IDO-specific T cells that can influence adaptive immune reactions in patients with cancer. Further, a recent phase I clinical trial demonstrated long-lasting disease stabilization without toxicity in patients with non-small-cell lung cancer (NSCLC) who were vaccinated with an IDO-derived HLA-A2-restricted epitope.

AB - Indoleamine 2,3-dioxygenase (IDO) is an immunoregulatory enzyme. Remarkably, we discovered IDO-specific T cells that can influence adaptive immune reactions in patients with cancer. Further, a recent phase I clinical trial demonstrated long-lasting disease stabilization without toxicity in patients with non-small-cell lung cancer (NSCLC) who were vaccinated with an IDO-derived HLA-A2-restricted epitope.

UR - https://www.scopus.com/pages/publications/84938717671

U2 - 10.4161/2162402X.2014.983770

DO - 10.4161/2162402X.2014.983770

M3 - Journal article

C2 - 25949864

SN - 2162-4011

VL - 4

SP - e983770

JO - OncoImmunology

JF - OncoImmunology

IS - 1

ER -

Indoleamine 2,3-dioxygenase vaccination

Abstract

Access to Document

Other files and links

Fingerprint

Cite this